Arbutus Biopharma (ABUS) Net Margin (2013 - 2026)

Arbutus Biopharma has disclosed Net Margin across 14 years of filings, most recently posting 94.74% for Q1 2026.

• Net Margin for Q1 2026 came in at 94.74%, up 148533.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 83.6% (up 127896.0% YoY), and the FY2025 annual result was 242.77%, up 89027.0% from the prior year.
• Net Margin came in at 94.74% for Q1 2026 at Arbutus Biopharma, up from 421.6% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 94.74% in Q1 2026 to a low of 1472.89% in Q3 2024.
• The 5-year median for Net Margin is 421.6% (2025), against an average of 620.58%.
• Across the five-year window, Net Margin plunged 104129 bps in 2024 and surged 148533 bps in 2026, its largest moves.
• Arbutus Biopharma's Net Margin stood at 351.19% in 2022, then tumbled by 156 bps to 900.33% in 2023, then increased by 12 bps to 794.09% in 2024, then jumped by 47 bps to 421.6% in 2025, then soared by 122 bps to 94.74% in 2026.
• The last three Net Margin figures came in at 94.74% (Q1 2026), 421.6% (Q4 2025), and 1461.25% (Q3 2025), per Business Quant data.